文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-FDG PET与99mTc骨显像评估骨病灶对转移性乳腺癌管理决策的临床相关差异

Assessment of Bone Lesions with 18F-FDG PET Compared with 99mTc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management.
PubMed 文献 · J Nucl Med · 2020-08-17

该回顾性研究比较了新诊断转移性乳腺癌患者基于18F-FDG PET联合增强CT与99mTc骨显像联合增强CT评估骨病灶时,多学科专家小组给出的虚拟管理推荐。结果显示,18F-FDG PET发现更多骨病灶,导致16%患者的管理推荐发生临床相关改变;26%患者因骨显像信息不足而被要求追加18F-FDG PET检查。

要点

  • 18F-FDG PET较骨显像多发现骨病灶,使16%患者管理推荐发生临床相关改变。
  • 26%患者因骨显像信息不足而需追加18F-FDG PET检查。
  • 新诊断转移性乳腺癌骨病灶评估可考虑将18F-FDG PET作为首选影像模态。

核心结论

  • 在新诊断转移性乳腺癌患者中,以18F-FDG PET替代99mTc骨显像评估骨病灶,可使16%患者的管理推荐发生临床相关差异。
  • 骨显像在超过四分之一患者中信息不足,导致追加18F-FDG PET检查的请求。
  • 基于上述数据,新诊断转移性乳腺癌骨病灶评估应考虑将18F-FDG PET作为首选影像模态。

研究设计与样本

  • 该研究为回顾性比较分析,纳入IMPACT-MBC研究(NCT01957332)在格罗宁根大学医学中心的所有患者。
  • 共评估102例患者,由多学科专家小组基于18F-FDG PET联合增强CT或99mTc骨显像联合增强CT分别给出虚拟管理推荐。
  • 专家小组可获取标准临床病理信息及骨外基线影像发现;若所有影像模态均未发现骨病灶,患者直接纳入分析而未经专家审阅。

主要发现

  • 在102例可评估患者中,共识别3473处明确骨病灶,其中增强CT识别39%、骨显像识别26%、18F-FDG PET识别87%。
  • 与骨显像联合增强CT相比,18F-FDG PET联合增强CT发现的额外骨病灶导致16%患者(95% CI,10%-24%)的转移性乳腺癌管理推荐发生改变。
  • 骨显像相较18F-FDG PET也改变了1例患者(1%;95% CI,0%-5%)的管理。
  • 26%患者(95% CI,19%-36%)因骨显像提供的信息不足而被要求追加18F-FDG PET检查。

关键数值与推荐

  • 临床相关管理差异定义为治疗意图不同(治愈性、非治愈性或无法确定)或系统性/局部治疗不同。
  • 18F-FDG PET联合增强CT相较骨显像联合增强CT导致管理推荐改变的患者比例为16%(95% CI,10%-24%)。
  • 骨显像相较18F-FDG PET导致管理推荐改变的患者比例为1%(95% CI,0%-5%)。
  • 因骨显像信息不足而追加18F-FDG PET检查的患者比例为26%(95% CI,19%-36%)。

临床怎么用

  • 对新诊断转移性乳腺癌患者评估骨病灶时,可考虑将18F-FDG PET作为首选影像模态。
  • 骨显像信息不足时,应追加18F-FDG PET检查以支持管理决策。

局限性

  • 该研究为回顾性探索性分析,管理推荐为虚拟推荐而非实际临床决策。
  • 研究仅纳入单中心IMPACT-MBC研究患者,样本量为102例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is unknown whether assessment of potential bone lesions in metastatic breast cancer (MBC) by 18F-FDG PET instead of 99mTc bone scintigraphy (BS) supports clinically relevant changes in MBC management. Therefore, we retrospectively compared management recommendations based on bone lesion assessment by 18F-FDG PET plus contrast-enhanced CT (ceCT) or BS plus ceCT, for patients with newly diagnosed MBC. Methods: Baseline ceCT, BS, and 18F-FDG PET for all patients included in the IMPACT-MBC study (NCT01957332) at the University Medical Center Groningen were reviewed for bone lesions. If bone lesions were found by any imaging modality, virtual MBC management recommendations were made by a multidisciplinary expert panel, based on either 18F-FDG PET plus ceCT or BS plus ceCT. The panel had access to standard clinicopathologic information and baseline imaging findings outside the skeleton. Clinically relevant management differences between the 2 recommendations were defined either as different treatment intent (curative, noncurative, or unable to determine) or as different systemic or local treatment. If no bone lesions were found by any imaging modality, the patients were included in the analyses without expert review. Results: In total, 3,473 unequivocal bone lesions were identified in 102 evaluated patients (39% by ceCT, 26% by BS, and 87% by 18F-FDG PET). Additional bone lesions on 18F-FDG PET plus ceCT compared with BS plus ceCT led to change in MBC management recommendations in 16% of patients (95% CI, 10%-24%). BS also changed management compared with 18F-FDG PET in 1 patient (1%; 95% CI, 0%-5%). In 26% (95% CI, 19%-36%) of patients, an additional 18F-FDG PET exam was requested, because BS provided insufficient information. Conclusion: In this exploratory analysis of newly diagnosed MBC patients, 18F-FDG PET versus BS to assess bone lesions resulted in clinically relevant management differences in 16% of patients. BS delivered insufficient information in over one fourth of patients, resulting in an additional request for 18F-FDG PET. On the basis of these data, 18F-FDG PET should be considered a primary imaging modality for assessment of bone lesions in newly diagnosed MBC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. van Es SC, Velleman T, Elias SG, et al. Assessment of Bone Lesions with 18F-FDG PET Compared with 99mTc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management. J Nucl Med. 2020. PMID: 32817140. doi:10.2967/jnumed.120.244640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。